RE:RE:Baxter Redaction Reveal?It is an interesting dilemma. I suspect that's why Baxter's finance participations to date have been in the form of a convertible bond and not just straight stock issuance. A bond is really just a loan and it provides lot's of cover in regards to slowly acquiring a part of another company. The convertible part is a sneaky way to avoid percentage ownership reports/filings etc.
But hey, don't go slouching on those convertibles because they didn't include a half warrant and generally speaking the conversion price was 20-30% above where the stock was trading at issuance. I personally, as a shareholder loved that we were able to raise on those terms at the time.
Anyways, I think it becomes a moot point after they 2nd milestone is made. I also suspect that it will put pressure on Spectral to do what they implied in their September investor presentation, in bold font nonethless, when they said, "potential opportunity to release crude data to a broader audience."
If Baxter gets to see it and then make their financial decisions, then so do we as shareholders. They said it in slide #13 and repeated it in slide #18.
With that being said, I would never do anything to even slightly taint the Tigris data and give it's critics an opening to criticize. And trust me there will be a lot of critics coming out of the woodwork. There are still patients to be enrolled and if posting the raw data results publically could be construed as a bias influence on a lead investigator at one of our sites, then the results cannot be released. We are already blessed with a confirmitory trial based on a sub-group analysis with the allowance of Bayesian statistics.
But yes, I'm dying to see the mortality benefit that was shown at 90.